BioLineRx Ltd. (BLRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.71
- As of
Kresmion compiles this page from BLRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BioLineRx Ltd. (BLRX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-23.
See the full BLRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BLRX on one page. Preview it with sample data, then open it live with a free account.
Preview the BLRX dossierActive events for BLRX
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in BLRX
- mediumEarnings below estimates
Q3-2015: Missed consensus by 47.1% - EPS $-0.12 vs $-0.0816 estimate
FREE, NO ACCOUNT
Every event on BLRX, as it fires
New filings, 13F moves and cross asset events on BLRX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
BLRX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 09071M304 · 2026Q2 | $48K | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 09071M304 · 2026Q2 | $46K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BLRX
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
Going concern statement
BLRX's 20-F filed Mar 23, 2026 states:
Management has concluded that there is substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
Read the 20-F on SEC EDGAR Every company with a going concern statement
More data on BLRX
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in BLRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on BLRX in the last 180 days.
Upstream: SEC EDGAR filings for BLRX
Kresmion, "BioLineRx Ltd. (BLRX) institutional holdings and SEC filings", data as of 2026-10-23, https://kresmion.com/research/BLRX. Upstream data: SEC EDGAR filings for BLRX.
Link to this data (HTML):
<a href="https://kresmion.com/research/BLRX">BioLineRx Ltd. (BLRX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow BLRX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to BLRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.